RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:178320

Acute lung injury

high confidenceDisorder

Publications

65,291

99.4th percentile

Trials

151

Interventional, condition-specific

Researchers

1,015

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    65,291 matched papers (42,250 in last 10 years) Source

  3. Phenotype characterisedPresent

    21 HPO annotations (e.g. Pneumonia; Respiratory distress; Hypoxemia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    1 FDA · 7 EMA designations (1 FDA orphan-indication approval) — e.g. L-citrulline Source

  6. Interventional trialPresent

    151 matched on ClinicalTrials.gov (9 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

21

Associated phenotypes · MONDO:0015796

  • Pneumonia
  • Respiratory distress
  • Hypoxemia
  • Increased circulating interleukin 6 concentration
  • Edema

Showing 5 of 21 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

8

Designations · 1 with FDA orphan-indication approval

  • FDA L-citrullineAcute Lung Injury · 2017-01-09 · Not FDA Approved for Orphan Indication
  • EMA aviptadilTreatment of acute lung Injury · 28/08/2006 · PositiveEMA designation
  • EMA bimosiamose disodiumTreatment of acute lung Injury · 27/05/2005 · PositiveEMA designation
  • EMA adrenomedullinTreatment of acute lung Injury · 09/06/2010 · PositiveEMA designation
  • EMA Human tumour necrosis factor alpha-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-CysTreatment of acute lung Injury · 08/10/2009 · PositiveEMA designation
  • EMA sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acidTreatment of acute lung Injury · 04/02/2002 · PositiveEMA designation
  • EMA Porcine lung surfactantTreatment of acute lung Injury · 19/09/2001 · WithdrawnEMA designation
  • EMA Asp-Arg-Val-Tyr-Ile-His-ProTreatment of acute lung Injury · 10/10/2012 · WithdrawnEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

63

Drugs / clinical candidates · MONDO_0015796

CTD chemicals (MyDisease.info)

184 associated chemicals · 374 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole · therapeutic
  • 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC · therapeutic
  • 14-hydroxydocosahexaenoic acid · therapeutic
  • 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid · therapeutic
  • 2-(2-fluorobenzamido)benzoate ethyl ester · therapeutic
  • 3-(4-methylphenylsulfonyl)-2-propenenitrile · therapeutic
  • Acetylcysteine · therapeutic
  • AGK2 compound · therapeutic
  • AK-1 compound · therapeutic
  • allyl sulfide · therapeutic
  • Ambroxol · therapeutic
  • Amifostine · therapeutic

Pathways: Alanine, aspartate and glutamate metabolism; Cysteine and methionine metabolism; Valine, leucine and isoleucine degradation; Tyrosine metabolism; Phenylalanine metabolism; Tryptophan metabolism; Phenylalanine, tyrosine and tryptophan biosynthesis; Glyoxylate and dicarboxylate metabolism

MyDisease.info · MONDO:0015796

Literature

Is anyone studying this?

65,291

65,291 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

65,291 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

42,250 in the last 10 years · high confidence · 99.4th percentile (publications denominator)

Phrase hits: 65,291 · MeSH hits: 2,464

Open Europe PMC search

Who's working on it?

1,015

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y20 papers · 2026

    Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.

    Papers in Europe PMC
  2. 02
    Zhang Y17 papers · 2026

    Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, 300100, People's Republic of China.

    Papers in Europe PMC
  3. 03
    Li J16 papers · 2026

    Department of Pharmacy, The Second Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong, 250033, PR China.

    Papers in Europe PMC
  4. 04
    Li X15 papers · 2026

    Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046099, China.

    Papers in Europe PMC
  5. 05
    Liu Y14 papers · 2026

    Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.

    Papers in Europe PMC
  6. 06
    Wang X14 papers · 2026

    Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, China; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, China.

    Papers in Europe PMC
  7. 07
    Li H12 papers · 2026

    Research and Translational Laboratory of Acute Injury and Secondary Infection, Minhang Hospital, Fudan University, Shanghai, 201199, China.

    Papers in Europe PMC
  8. 08
    Wu Y12 papers · 2026

    Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, 300100, People's Republic of China.

    Papers in Europe PMC
  9. 09
    Chen X10 papers · 2026

    Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.

    Papers in Europe PMC
  10. 10
    Li Y10 papers · 2026

    Department of Pediatrics, The Second Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong, 250033, PR China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

151

interventional trials for this specific condition

151 interventional trials matched this specific condition name; 9 currently recruiting in our sample. 4,199 trials are registered for injury, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

151 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99th percentile).

high confidence · 99th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

151 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: injury

4,199

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

88 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 41 · after dedupe 41 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 41 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (41)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Acute lung injury — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Acute lung injury"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Acute Lung Injury

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Acute lung injury"

Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 151 interventional · 88 observational · 1 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"injury"

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T08:48:08.558Z